A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) Anlotinib Plus CapeOx Bevacizumab Plus CapeOx

  • End date
    Jun 28, 2024
  • participants needed
  • sponsor
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Updated on 28 October 2021


A clinical study to compare the efficacy and safety of AK105 plus anlotinib and Capecitabine/Oxaliplatin (CapeOx) , anlotinib plus CapeOx, bevacizumab plus CapeOx. A total of 120 cases will be enrolled to the group.

Condition Unresectable Metastatic Colorectal Cancer
Treatment bevacizumab, CAPEOX, Anlotinib hydrochloride capsule, AK105 injection
Clinical Study IdentifierNCT05068206
SponsorChia Tai Tianqing Pharmaceutical Group Co., Ltd.
Last Modified on28 October 2021


Yes No Not Sure

Inclusion Criteria

The subjects shall volunteer to join in the research and sign the informed consent under the good compliance
Aged: 18-75 (calculated on the date of signing informed consent); the physical status of Eastern cooperative oncology group 0~1; expected lifetime3 months
Unresectable and untreated metastatic colorectal adenocarcinoma patients diagnosed by histopathology Union for International Cancer Control (UICC) ,American Joint Committee on Cance( AJCC) tumor node metastasis staging system for colorectal cancer (8th edition in 2017) is clearly IV stage
Subjects who have not received systematic treatment for colorectal cancer before, including chemotherapy, targeted therapy and immunotherapy; Subjects with tumor recurrence or metastasis at least 6 months after the end of previous adjuvant or neoadjuvant chemotherapy
It can provide previously stored tumor tissue specimens or biopsy to collect tumor focus tissues for detecting programmed death 1 expression and kirsten rat sarcoma viral oncogene/neuroblastoma rat sarcoma viral oncogene mutation
According to RECIST 1.1 criterion, there is at least one measurable lesion. It is required that the selected target lesion has not received local treatment before, or the selected target lesion is located in the previous local treatment area, but it is determined as progressive disease by imaging examination
Good organ function (no blood transfusion, no hematopoietic stimulating factor, no infusion of albumin or blood products within 14 days before randomization)
Female subjects of childbearing age should agree that contraceptive measures (such as abstinence, intrauterine device, contraceptive pills or condoms) must be used during the study and within 6 months after the end of the study; Serum pregnancy test was negative within 7 days before the study was enrolled, and it must be a non-lactating subject; Male subjects should agree that contraception must be used during the study period and within 6 months after the end of the study period

Exclusion Criteria

) Combined diseases and medical history
Other malignant tumors have occurred or are currently suffering at the same time within 3 years. The following conditions can be included: cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumor [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invasive basement membrane)]
Factors which affecting oral administration of drugs (such as inability to swallow, chronic diarrhoea and ileus, etc.)
There is or tends to be gastrointestinal bleeding or perforation within 4 weeks before inclusion
Subjects with ulcerative colitis and Crohn's disease; Subjects with active inflammatory bowel disease within 4 weeks before inclusion
Uncontrollable pleural effusion and ascites requiring repeated drainage, and moderate and above hydropertcardium
Unmitigated toxic reactions above Common Terminology Criteria for Adverse Events S1 due to any previous treatment, excluding alopecia
Major surgical treatment, open biopsy or obvious traumatic injury were received within 28 days before inclusion (except tissue biopsy under gastrointestinal endoscope)
Imaging(CT or MRI) showed that the tumor invaded large blood vessels or had unclear boundary with blood vessels
Subjects with hematemesis and hematochezia symptoms within 3 months before screening, and the daily bleeding volume is 2. 5 ml, or any bleeding event Common Terminology Criteria for Adverse Events S3, or subjects with any bleeding signs or medical history judged by researchers to be unsuitable for inclusion regardless of severity
There are unhealed wounds, ulcers or fractures
Arteriovenous thrombosis occurred within 6 months, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc
Subjects who have a history of psychotropic drug abuse and can't quit
Subjects with any severe and/or uncontrolled diseases, including
Uncontrolled hypertension (systolic blood pressure 150 mmHg or diastolic blood
pressure 100 mmHg after standard antihypertensive treatment); Suffering from
unstable angina pectoris/ S2 or over cardiogenic chest pain; Myocardial
infarction occurred within 12 months before randomization; S1or over heart
failure (New York Heart Association (NYHA) grade); Restrictive cardiomyopathy
S2 or over atrioventricular block, arrhythmia that cannot be stably controlled
by drugs [including QTc 450 ms (male) and QTc 470 ms (female)], and arrhythmia
that may have potential influence on experimental treatment; Active infection
( Common Terminology Criteria for Adverse Events S2 infection); Decompensated
cirrhosis, active hepatitis _; (_ Active hepatitis (hepatitis B reference
HBsAg positive, and HBV DNA positive (> 2500 copies/ml or > 500IU/ml)
Hepatitis C reference: HCV antibody positive, and HCV virus titer detection
value exceeds the upper limit of normal value); Note: Subjects with positive
hepatitis B surface antigen or core antibody and hepatitis C patients who meet
the entry conditions need continuous antiviral treatment to prevent virus
activation. ) Subjects with renal failure requiring hemodialysis or peritoneal
dialysis; Have a history of immunodeficiency, including HIV positive or
suffering from other acquired and congenital immunodeficiency diseases, or
have a history of organ transplantation; Diabetes mellitus is poorly
controlled (fasting blood glucose (FBG) > 10mmol/L) Urine routine indicates
that urine protein is + +, and it is confirmed that 24-hour urine protein
quantity is > 1.0 g; Subjects who have a definite history of neurological or
mental disorders, including epilepsy or dementia, and need treatment
) Tumor-related symptoms and treatment
Have received surgery (except previous diagnostic biopsy), radiotherapy, chemotherapy or other anti-cancer therapy within 4 weeks before inclusion (wahsout period is calculated from the end of the last treatment); Note: Those who have received local radiotherapy in the past can be enrolled if the following conditions are met: the end of radiotherapy is more than 4 weeks from the start of study treatment (brain radiotherapy is more than 2 weeks), and the target lesions selected in this study are not in the radiotherapy area; Or the target lesion is located in the radiotherapy area, but the progress has been confirmed
Within 2 weeks before joining the group, subjects who received ready-for-use traditional Chinese medicine (including Compound Mylabris Capsule, Kang'ai Injection, Kanglaite Capsule/Injection, Aidi Injection, Brucea javanica Oil Injection/Capsule, Xiaoaiping Tablet/Injection, Cinobufagin Capsule, etc.) with anti-tumor indications specified in National Medical Products Administration approved drug instructions
Subjects who have previously received anti-PD-1 or anti-PD-L1/PD-L2 preparations or other treatments acting on T cell co-stimulation targets or checkpoints
Previous postoperative adjuvant therapy containing anti-vascular or anti-epidermal growth factor receptor targeted drugs (including but not limited to bevacizumab, cetuximab, panitumumab, aflibercept, regorafenib, etc.)
Central nervous system metastasis with symptoms or symptoms control time less than 2 months
) Research therapy related
Vaccination history of live attenuated vaccine within 28 days before enrollment or plan to vaccinate live attenuated vaccine during the study period
Subjects who are known to be allergic to research drugs or excipients, or allergic to similar drugs
Active autoimmune diseases requiring systemic treatment (such as the use of disease-relieving drugs, corticosteroids or immunosuppressants) occurred within 2 years before enrollment. Alternative therapies (such as thyroxine, insulin or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic treatment
Diagnosed as immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy (dose > 10mg/day prednisone or other equivalent hormone), and continuing to be used within 2 weeks after the first administration
Participated in clinical trials of other anti-tumor drugs within 4 weeks before joining the group (washout period was calculated from the end of the last treatment)
According to the researcher's judgment, there are accompanying diseases that seriously endanger the safety of the subjects or affect the completion of the study, or there are other reasons why the subjects are not suitable for enrollment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note